DUBLIN, December 03, 2021--(BUSINESS WIRE)--The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's), By Type (Genomic, Proteomic), By End-use, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
The global neurological biomarkers market size is expected to reach USD 16.14 billion by 2028. The market is expected to grow at a CAGR of 12.9% from 2020 to 2028. Increasing funding for the R&D of neurological biomarkers to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products for the diagnosis of neurological biomarkers is expected to propel market growth over the forecast period.
The National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation. Thus, the presence of organizations offering funds at various stages of research is anticipated to drive market growth. For instance, the University of North Texas Health Science Center (HSC) was awarded around USD 45.5 million funds from the National Institutes of Health (NIH) to support research regarding health disparities in Alzheimer's and brain aging. NIH is offering additional funds for biomarkers research for the ongoing Health and Aging Brain Among Latino Elders (HABLE) study.
Increasing product launches are also expected to drive market growth. For instance, in January 2021, Abbott received FDA 510K clearance for its rapid handheld traumatic brain injury test that measures UCH-L1 and GFAP biomarkers. The results of this test are available within 15 minutes, and it helps clinicians assess the need to perform a CT scan. The rapid turnaround time of this test will help physicians plan and deliver treatment on time.
In August 2018, Olink Proteomics AB introduced a new biomarker panel Olink NEURO EXPLORATORY for the expansion of a portfolio of high-quality protein assays. This product includes a high-performance assay for neurofilament light polypeptide, a significant biomarker for traumatic brain injury and degenerative neurological diseases.
However, the lack of reimbursement coverage for the biomarkers impedes market growth. Currently, only certain, restricted forms of biomarker tests for dementia symptoms are covered by Medicare and other health insurance programs and their use must be justified based on the symptoms and specific requirements of the individual.
The reimbursement for Alzheimer's disease is also not provided by most of the insurance providers, such as the Blue Cross and Blue Shield Association. The reimbursement coverage for neurological biomarker testing in developing countries, such as India and China, is even lesser, as these countries have low insurance penetration and very little awareness about biomarker testing.
Neurological Biomarkers Market Report Highlights
Increasing collaborations and public-private partnerships for research initiatives may fuel market growth
For instance, in February 2018, MJFF in collaboration with the NIH and five life-sciences companies provided USD 24 million as a research grant for the development of neurological biomarkers
In 2020, the proteomic biomarkers segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period
The Parkinson's disease segment led the market in 2020. An increasing number of clinical trials for Parkinson's disease drugs and the growing prevalence of the disease is expected to drive the segment growth in the years to come
North America was the largest regional market in 2020 owing to the high disease burden, acceptance of biomarkers for diagnostic, prognostics, & drug development purposes, and increase in research funding
Asia Pacific is anticipated to witness the fastest CAGR over the forecast period owing to a rising number of clinical trials being conducted in developing countries, such as India and China, increasing disease burden, and growing need for targeted drugs in the central nervous system
Johnson & Johnson Services, Inc.
Bio-Rad Laboratories, Inc.
Alseres Pharmaceuticals, Inc.
Banyan Biomarkers, Inc.
Myriad RBM (Myriad Genetics, Inc.)
Thermo Fisher Scientific, Inc.
Merck & Co. Inc.
Key Topics Covered:
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Model Details
1.7 Research Assumptions
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Neurological Biomarkers Market Variables, Trends, and Scope
3.1 Neurological Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Alzheimer's Disease
3.3.2 Parkinson's Disease
3.3.3 Multiple Sclerosis
3.3.4 Autism Spectrum Disorder
3.4 Market Dynamics
3.4.1 Market Driver Analysis
18.104.22.168 Increasing Prevalence Of Neurological Diseases
22.214.171.124 Technological Advancements
126.96.36.199 Increased Funding For R&D In Biomarkers
3.4.2 Market Restraint Analysis
188.8.131.52 Lack of consumer awareness
184.108.40.206 Reimbursement policies
3.5 Neurological Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis - Porter's
3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2017 - 2028 (USD Million)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2020 & 2028
4.3 Segment Dashboard
4.4 Global Neurological Biomarkers Market, by Type, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2017 - 2028 (USD Million)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2020 & 2028
5.3 Segment Dashboard
5.4 Global Neurological Biomarkers Market, by Application, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.5.1 Alzheimer's Disease
5.5.2 Parkinson's Disease
5.5.3 Multiple Sclerosis
5.5.4 Autism Spectrum Disorder
Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2017 - 2028 (USD Million)
6.1 Definition and Scope
6.2 End-use Market Share Analysis, 2020 & 2028
6.3 Segment Dashboard
6.4 Global Neurological Biomarkers Market, by End Use, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.5.1 Hospital & Hospital Laboratories
6.5.2 Independent Clinical Diagnostic Centers
6.5.3 Research Organizations and Others
Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020 & 2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share and Leading Players, 2020
7.5.1 North America
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East And Africa
7.6 SWOT Analysis
7.6.1 NORTH AMERICA
7.6.3 Asia Pacific
7.6.4 Latin America
7.6.5 Middle East And Africa
7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
7.7.1 North America
220.127.116.11 North America market estimates and forecast, 2017 - 2028 (USD Million)
18.104.22.168 The U.S.
22.214.171.124 Europe Neurological Biomarkers market, 2017 - 2028 (USD Million)
126.96.36.199 The U.K.
7.7.3 Asia Pacific
188.8.131.52 Asia Pacific Neurological Biomarkers market, 2017 - 2028 (USD Million)
184.108.40.206 South Korea
7.7.4 Latin America
220.127.116.11 Latin America Neurological Biomarkers market, 2017 - 2028 (USD Million)
18.104.22.168 MEA Neurological Biomarkers market, 2017 - 2028 (USD Million)
22.214.171.124 South Africa
126.96.36.199 Saudi Arabia
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 New Product Launches
8.1.2 Mergers And Acquisitions
8.1.3 Partnerships And Licensing Agreements
8.1.4 Conferences And Campaigns
8.2 Company Categorization
For more information about this report visit https://www.researchandmarkets.com/r/g36zw
View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005173/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900